Skip to main content
Log in

Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine

  • Short Communication
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

Two subjects from each of the three groups of homozygous rapid, heterozygous, and homozygous non-metabolizers (N-oxidation) of sparteine received a single oral dose of debrisoquine. The urinary ratio of debrisoquine/4-hydroxy-debrisoquine, reflecting the individual's capacity to C-hydroxylate debrisoquine, was closely related to his phenotype for sparteine metabolism. This indicates that the two metabolic reactions are controlled by similar if not identical genetic factors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Eichelbaum, M.: Ein neuentdeckter Defekt im Arzneimittel-stoffwechsel des Menschen: Die fehlende N-Oxydation des Spartein. Habilitationsschrift, University of Bonn (1975)

  2. Eichelbaum, M., Spannbrucker, N., Dengler, H. J.: Lack of N-oxidation of sparteine in certain healthy subjects. Sixth International Congress of Pharmacology, Helsinki, July 20–25, 1975, p. 1071.

  3. Eichelbaum, M., Spannbrucker, N., Steinecke, B., Dengler, H. J.: Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur. J. Clin. Pharmacol.16, 183–187 (1979a)

    Google Scholar 

  4. Eichelbaum, M., Spannbrucker, N., Dengler, H. J.: Influence of the defective metabolism of sparteine on its pharmacogenetics. Eur. J. Clin. Pharmacol.16, 189–194 (1979b)

    Google Scholar 

  5. Idle, J. R., Mahgoub, A., Lancaster, R., Smith, R. L.: Hypotensive response to debrisoquine and hydroxylation phenotype. Life Sci.22, 979–984 (1978)

    Google Scholar 

  6. Lennard, M. S., Silas, J. H., Smith, A. J. Tucker, G. T.: Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detection. J. Chromatogr.133, 161–166 (1977)

    Google Scholar 

  7. Mahgoub, A., Idle J. R., Dring, L. G., Lancaster, R., Smith, R. L.: Polymorphic hydroxylation of debrisoquine in man. Lancet1977/II, 584–586

    Google Scholar 

  8. Mitchell, J. R., Cavanaugh, J. H., Dingell, J. V., Oates, J. A.: Guanethidine and related agents. II. Metabolism by hepatic microsomes and its inhibition by drugs. J. Pharmacol. Exp. Ther.172, 108–114 (1970)

    Google Scholar 

  9. Sjöqvist, F., Borgå, O., Orme, M. L'E.: Fundamentals in Clinical Pharmacology. In: Drug Treatment, 2nd Ed. Avery, G. S. (ed.), pp. 1–61. Auckland, New Zeland: Adis Press 1980

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Additional information

At Karolinska Institutet on temporary leave from Department of Angiology and Geriatrics, Medical School of Lübeck, Federal Republic of Germany.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bertilsson, L., Dengler, H.J., Eichelbaum, M. et al. Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine. Eur J Clin Pharmacol 17, 153–155 (1980). https://doi.org/10.1007/BF00562624

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00562624

Key words

Navigation